Document Detail

Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
MedLine Citation:
PMID:  17085669     Owner:  NLM     Status:  MEDLINE    
PURPOSE: Lysophosphatidic acid acyltransferase (LPAAT)-beta catalyzes the conversion of lysophosphatidic acid to phosphatidic acid, an essential component of several signaling pathways, including the Ras/mitogen-activated protein kinase pathway. Inhibition of LPAAT-beta induces growth arrest and apoptosis in cancer cell lines, implicating LPAAT-beta as a potential drug target in neoplasia. EXPERIMENTAL DESIGN: In this study, we investigated the effects of CT32228, a specific LPAAT-beta inhibitor, on BCR-ABL-transformed cell lines and primary cells from patients with chronic myelogenous leukemia. RESULTS: CT32228 had antiproliferative activity against BCR-ABL-positive cell lines in the nanomolar dose range, evidenced by cell cycle arrest in G2-M and induction of apoptosis. Treatment of K562 cells with CT32228 led to inhibition of extracellular signal-regulated kinase 1/2 phosphorylation, consistent with inhibition of mitogen-activated protein kinase signaling. Importantly, CT32228 was highly active in cell lines resistant to the Bcr-Abl kinase inhibitor imatinib. Combination of CT32228 with imatinib produced additive inhibition of proliferation in cell lines with residual sensitivity toward imatinib. In short-term cultures in the absence of growth factors, CT32228 preferentially inhibited the growth of granulocyte-macrophage colony-forming units from chronic myelogenous leukemia patients compared with healthy controls. CONCLUSION: These data establish LPAAT-beta as a potential drug target for the treatment of BCR-ABL-positive leukemias.
Paul La Rosée; Taiping Jia; Shadmer Demehri; Nicolai Härtel; Peter de Vries; Lynn Bonham; David Hollenback; Jack W Singer; Junia V Melo; Brian J Druker; Michael W Deininger
Related Documents :
11238609 - Translocation of the b cell antigen receptor into lipid rafts reveals a novel step in s...
14749119 - Resistance to antineoplastic therapy. the oncogenic tyrosine kinase-bcl-x(l) axis.
23119229 - Phosphorylation of p47phox is required for receptor-mediated nadph oxidase/nox2 activat...
15070699 - Bcr/abl kinase inhibition by imatinib mesylate enhances map kinase activity in chronic ...
12204529 - Resistance in the land of molecular cancer therapeutics.
16627759 - Roles of tyrosine 589 and 591 in stat5 activation and transformation mediated by flt3-itd.
9191889 - Uncoupling of t-cell antigen receptor and downstream protein tyrosine kinases in common...
11702779 - Two zinc finger proteins, oma-1 and oma-2, are redundantly required for oocyte maturati...
10727429 - Protein kinase c-beta contributes to nadph oxidase activation in neutrophils.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical cancer research : an official journal of the American Association for Cancer Research     Volume:  12     ISSN:  1078-0432     ISO Abbreviation:  Clin. Cancer Res.     Publication Date:  2006 Nov 
Date Detail:
Created Date:  2006-11-06     Completed Date:  2007-01-09     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9502500     Medline TA:  Clin Cancer Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  6540-6     Citation Subset:  IM    
Division of Hematology and Medical Oncology, Oregon Health and Sciences University, Portland, Oregon.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acyltransferases / pharmacology*
Antineoplastic Agents / pharmacology*
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Apoptosis / drug effects
Cell Line, Tumor
Cell Proliferation / drug effects
Drug Resistance, Neoplasm*
Drug Synergism
Enzyme Inhibitors / pharmacology*
Extracellular Signal-Regulated MAP Kinases / drug effects
Hematopoietic Stem Cells / drug effects
Hydrocarbons, Halogenated / pharmacology*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Phosphorylation / drug effects
Piperazines / pharmacology*
Pyrimidines / pharmacology*
Triazines / pharmacology*
Reg. No./Substance:
0/Antineoplastic Agents; 0/CT-32228; 0/Enzyme Inhibitors; 0/Hydrocarbons, Halogenated; 0/Piperazines; 0/Pyrimidines; 0/Triazines; 152459-95-5/imatinib; EC 2.3.-/Acyltransferases; EC acyltransferase; EC Signal-Regulated MAP Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  2-methoxyestradiol, an endogenous mammalian metabolite, radiosensitizes colon carcinoma cells throug...
Next Document:  Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-...